Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 10;27(8):2949–2958. doi: 10.1245/s10434-020-08304-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Overall survival of all resections in cohort A versus cohort B. The median overall survival of all patients who underwent pancreatoduodenectomy in cohort A was 21 months (95% CI 15.6–26.4), compared with 18 months (95% CI 14.5–21.5) in cohort B (p = 0.238). b Overall survival of all resections with PDAC on final pathological examination of cohort A versus cohort B. The median overall survival after pancreatoduodenectomy for PDAC was 17 months (95% CI 15.0–19.0) versus 18 months (95% CI 14.7–21.3) in both cohorts (p = 0.943). c Overall survival of patients in cohorts A and B with negative lymph node (N0) status, positive lymph node (N +) status, PALN involvement (PALN +), and metastasized (M1) disease. Median overall survival was 65, 18, 9, and 3 months, respectively (p < 0.001). d Overall survival of patients in cohorts A and B with PDAC on final pathological examination, with N0, N+, PALN+, and M1 status. Median overall survival was 35, 17, 9, and 3 months, respectively (p < 0.001). PDAC pancreatic ductal adenocarcinoma, PALN para-aortic lymph node